- Reduced price
Reference: 5004
100 rozpoznań - głowa i szyja (z serii Pocket Radiologist Top 100 diagnoses)
Author: Rick Harnsberger
Order to parcel locker
easy pay
Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details
Pay with a quick bank transfer, payment card or cash on delivery. Click for more details
If you are a consumer, you can return the goods within 14 days. Click for more details
Data sheet
Tentative TOC:
Introduction:
Chapter 1.0 Development and Structure of the Lymphoid System
gross anatomy of the human immune system
lymphatic endothelial cells, heterogeneity of, and lymph node microscopic structure
lymph node function; afferent lymph cellular components
role of the gut microbiome in immune system development
specific functions related to the spread of cancer
cancer-induced lymphangiogeneis; sentinel LNs
Chapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins
immunoglobulin isotypes
the structure of immunoglobulins
the genetics of immunoglobulin diversity
antibody-dependent cellular cytotoxicity
heavy-chain C domain and role of glycosylation
the development of humanized monoclonals
Chapter 3.0 The Role of the Complement System in Cancer
complement system activation pathways (classical, alternative and lectin)
the role of complement activation in cancer progression
complement regulatory proteins (CRPs) and cancer
the role of compliment activation in the tumor microenvironment enhances tumor growth
complement-dependent cytotoxicity in immune therapy of cancer
formation of the membrane attack complex (MAC)
potential application of anti-complement cancer therapies (C3aR/C5aR/IL-10 pathway)
Chapter 4.0 Cancer as Non-Self
4.1 primary generator of tumor-specific transplantation type antigens
4.2 character of non-self, tumor associated antigens
4.3 immune surveillance - innate immunity
4.4 distinguishing between self and non-self
4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C proteins
4.6 NK cells
Chapter 5.0 The Adaptive Immune Response in Cancer
the diversity of active tumor antigen receptors
target specificity without limits in cancer-receptor variability
tumor antigen presentation; dendritic cells
immune response stimulation against the cancer
Cytotoxic T-cells and T-regulatory cells
B-cells and antibodies
Chapter 6.0 The Science of Innate Immunity
6.1 critical regulator of human inflammatory disease
6.2 anatomic and physiologic barriers to pathogens - cancer causing viruses
6.3 centrally a limited number of critical receptors
6.4 the character of the inflammatory response
6.5 lack of ability to form memory
6.5 role in activating subsequent adaptive immune response
Chapter 7.0 Immune Surveillance
7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize)
7.2 evidence for immune surveillance today
7.3 cancer in the immunocompromised host
Chapter 8.0 Cancer - Avoiding Immune Detection
8.1 cancer and the presence of immune resistance
8.2 concept for the development of tumor cell tolerance
Chapter 9.0 Active Immunization Against Cancer and Cell-based Therapies
9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs)
9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens
9.3 B7 co-activating receptor
9.4 vaccines
Chapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy
(modulating cell-mediated immune mechanisms)
10.1 the role of and application of check point blockade
10.2 the role and application of cell-based therapies including CAR-T cell therapies
10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics
Chapter 11.0 The Clinical Application of Immunotherapeutics
11.1 in melanoma cancer
11.2 in breast cancer
11.3 in pancreatic cancer
11.4 in colon and rectum cancer
11.5 in prostate cancer
11.6 in leukemias and hematologic malignancies
11.7 in other malignancies
Chapter 12.0 Cancer Immunotherapy in the Presence of COVID-19
12.1 immune response to coronavirus-2 infection
12.2 CD8+ T cell depression during chronic viral infection and cancer
12.3 checkpoint inhibitors in cancer patients with coronavirus infection
12.4 coronavirus depletion of CD4+ T cells
Reference: 5004
Author: Rick Harnsberger
Reference: 5213
Author: Sjirk J. Westra